Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from ArcticZymes Technologies ASA ( (DE:B4V) ).
ArcticZymes Technologies ASA has completed a share buyback program, acquiring 31,365 shares at an average price of NOK 22.5037 each. These shares, representing approximately 0.061% of the company’s total shares, will be used to fulfill obligations under its share-based incentive programs, allowing employees to purchase shares at a 15% discount. This move is part of the company’s strategic financial management, potentially enhancing shareholder value and aligning employee interests with company performance.
More about ArcticZymes Technologies ASA
Headquartered in Tromsø, Norway, ArcticZymes Technologies ASA is a publicly listed company specializing in the provision of novel and high-quality enzymes for molecular research, diagnostics, and biomanufacturing. With over 30 years of expertise, the company focuses on developing and manufacturing salt-active nucleases and other specialty enzymes inspired by the Arctic environment, ensuring robust performance under demanding conditions. ArcticZymes is ISO 13485 certified and adheres to relevant ICH GMP standards.
Average Trading Volume: 39,304
Current Market Cap: NOK1.12B
See more insights into B4V stock on TipRanks’ Stock Analysis page.